Physician profile
Garrett B Smith
NPI 1669587630
$7,491.79
in general payments reported to CMS, 2019-2025
55 companies · $882 in 2025
The $882 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $1,921 · 2021: $1,285 · 2022: $873 · 2023: $918 · 2024: $895 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,694.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,302.65 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Medtronic Minimed, INC. | $1,035.54 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $732.52 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $402.23 | 2019-2025 | Veozah |
| Abbott Laboratories | $300.49 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $272.66 | 2019-2020 | |
| Lilly USA, LLC | $269.92 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $238.78 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $218.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $215.52 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $198.67 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $198.51 | 2019-2022 | |
| Mylan Specialty L.P. | $165.69 | 2020-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $151.19 | 2020-2023 | Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $145.09 | 2022-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $144.53 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Impel Pharmaceuticals INC. | $103.84 | 2022-2023 | Trudhesa |
| Boston Scientific Corporation | $81.49 | 2019-2023 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.71 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $74.42 | 2025 | Voquezna |
| Bausch Health US, LLC | $71.31 | 2021-2024 | Aplenzin |
| Ironshore Pharmaceuticals INC. | $71.21 | 2019-2023 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.98 | 2019-2021 | |
| Axsome Therapeutics, INC. | $62.09 | 2024-2025 | Sunosi, Symbravo |
| Corium, LLC | $60.09 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $59.04 | 2020-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Dynavax Technologies Corporation | $55.64 | 2020-2023 | Heplisav-B |
| Edwards Lifesciences Corporation | $54.69 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Mannkind Corporation | $52.99 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $47.71 | 2021 | |
| Medtronic, INC. | $43.54 | 2024-2025 | Venaseal |
| Cranial Technologies, INC | $31.90 | 2024-2025 | Doc Band |
| Neurocrine Biosciences, INC. | $31.47 | 2024-2025 | Ingrezza |
| Organon LLC | $31.46 | 2022-2025 | Nexplanon |
| Lucid Diagnostics INC. | $30.93 | 2023 | |
| Supernus Pharmaceuticals, INC. | $28.81 | 2022 | |
| Dexcom, INC. | $28.62 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $28.57 | 2025 | Spravato |
| Nestle Healthcare Nutrition INC. | $23.48 | 2021 | |
| Smith+Nephew, INC. | $21.47 | 2025 | Grafix Pl |
| Tris Pharma INC | $20.77 | 2023 | Dyanavel Xr |
| Horizon Therapeutics Plc | $20.70 | 2022 | |
| Grifols USA, LLC | $20.66 | 2024 | Prolastin-C Liquid |
| Biohaven Pharmaceutical Holding Company LTD. | $20.65 | 2022 | |
| Indivior INC. | $20.57 | 2024 | Sublocade |
| Daiichi Sankyo INC. | $19.91 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.45 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $18.19 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $16.19 | 2023 | Seglentis, Livalo |
| Upsher-Smith Laboratories LLC | $15.89 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.55 | 2025 | Caplyta |
| C. R. Bard, INC. & Subsidiaries | $14.17 | 2024 | Bd Onclarity |
| Alfasigma USA, INC. | $13.45 | 2020 | |
| Pear Therapeutics (US), INC. | $13.19 | 2022 | |
| Sobi, INC | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.